PMKB
PMKB
Genes
Variants
Interpretations
Tumor Types
Primary Sites
Activity
Login
KIT
Information
View History
Pending Review
Interpretation 2168
Tier 1
KIT
Variants
KIT D820Y
KIT D820A
KIT D820E
KIT D820G
Primary Sites
Unknown
Tumor Types
Thymic Carcinoma
Interpretation
Sorafenib
Citations
Bisagni G, et al. Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol 2009;4(6):773-5
Montemurro M, et al. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. Eur J Cancer 2013;49(5):1027-31
Park SH, et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Invest New Drugs 2012;30(6):2377-83
Last updated: 2018-04-06 15:15:16 UTC
PMKB Bot
Genes
Variants
Interpretations
Tumor Types
Primary Sites
Activity